Search Results 581-590 of 18158 for alopecia

1. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...

2. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

   Any persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 drug-related toxicity (except alopecia, erectile impotence ...

3. Study of MK-8242 Alone and in Combination with Cytarabine in Participants with Acute Myelogenous Leukemia (P07649) - Mayo Clinic

   Recovered from the effects of any prior surgery, radiotherapy or anti-neoplastic treatment, with the exception of alopecia; Must be able to swallow, retain ...

4. Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies - Mayo Clinic

   Participants with Grade 2 neuropathy or Grade 2 alopecia are eligible. - Active idiopathic thrombocytopenic purpura. - Stem cell transplant < 100 days prior ...

5. Mayo Clinic Minute Treatment for hair loss and women Video Audio Vivien Williams What woman doesn’t want thick, luxurious

   What can you do about it? Well, Dr. Drage says that depends on why you're losing your hair. But, for the most common form of hair loss, over-the-.

6. A Study Of IDRX-42 Versus Sunitinib In Participants With Metastatic And/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3) - Mayo Clinic

   Note: Treatment-related Grade > 1 alopecia, treatment-related Grade 2 peripheral neuropathy, and treatment-related Grade 2 hypothyroidism on a stable dose ...

7. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   Adverse events due to previous anti-tumor therapy have not recovered to ≤ CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤ CTCAE Grade 2.

8. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...

9. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer - Mayo Clinic

   Relevant toxicities of prior therapies must have resolved to ≤Grade 1, except for oxaliplatin-related neuropathy or alopecia;; Participant with myocardial ...

10. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

    Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) ...